Clinical trial · Observational
OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer
NCT07153705CI-TRIAL-00094486not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To study the performance of OCS products based on exosome detection technology in monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment, and to explore reliable methods for monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- OCS product inspection
- timeFrame
- Before the operation
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: 1. Women over 18 years old; 2. Pathologically confirmed as stage I-IV primary epithelial ovarian malignant tumor; 3. ECOG \< 2; 4. The expected survival period exceeds 6 months; 5. CA125 ≤ 35 U/ml before initial treatment; 6. Undergo surgery and adjuvant chemotherapy; 7. The period between diagnosis and enrollment does not exceed 8 weeks; 8. Be willing to provide blood samples for OCS testing during the research process; 9. Sign the informed consent form. Exclusion criteria 1. Have had other malignant tumors within the last five years; 2. Have received any treatment for ovarian cancer; 3. Benign ovarian mass; 4. Non-primary ovarian tumors; 5. Combined with other malignant tumors; 6. Patients receiving neoadjuvant therapy; 7. Pregnancy.
References
Publications (0)
Data not yet available
No reference posted for this study.